Introducing EnFix RC™

Demineralized Bone Fiber Implant for Rotator Cuff Enthesis Repair

”EnFix RC™ is designed to minimally disrupt the way rotator cuff repairs are performed, simplifying the delivery of the product into the interface between the bone and the tendon flipping the script compared to most of the products today for augmentation.” Nikhil Verma, MD. Professor and Director, Division of Sports Medicine, Fellowship Director, Department of Orthopedics, Rush University Medical Center, Team Physician Chicago White Sox and Chicago Bulls, Board Director, Tetrous, Inc.

With EnFix RC™ - It's All About the Enthesis™

Play Video

EnFix RC™ - A Procedure Specific Solution that is Minimally Disruptive to the Rotator Cuff Workflow

Play Video

The Science Behind EnFix RC™

H+E histology demonstrates reformation of the enthesis at 12 weeks following treatment with EnFix RC™ in a pre-clinical sheep study.

EnFix RC™ is specifically designed to address Enthesis Failure Syndrome by promoting the remodeling of tissue approximating that of the natural bone-tendon enthesis.

Our technology has a successful clinical legacy and has been extensively studied in bone and tendon healing demonstrating both osteoconductivity and osteoinductivity. The demineralized bone fibers in EnFix RC™ promote optimal biologic performance while easily integrating into current surgical techniques.

The Bone Textile™ technology yields long and strong fibers that promote cell wicking, cell adhesion and cell proliferation, versus the highly variable short shavings that are produced by other processes. The FormLok™ technology imparts shape retention to the device, even when immersed in liquid, as is often required for use in arthroscopic surgery.

How EnFix RC™ Works

Play Video
See the Full EnFix RC™ Video

EnFix RC™ Is Available In Two Sizes

TET-RC-45

Fits suture anchors 4.5 - 5.5 mm

TET-RC-55

Fits suture anchors 5.5 - 6.5 mm

Rotator Cuff Market

$3 Billion

In the United States alone, more than 500,000 rotator cuff repairs (RCR) are performed annually at a cost of $3 billion.

20% to 70%

20% to 70% of RCRs structurally fail. This failure rate is likely to rise given an aging population with greater functional demands.

RCR Augmentation

Most augmentation products have focused on overlays / patches to reinforce the tendon.

Tetrous has flipped the script by developing methods to enhance healing at the tendon-to-bone interface

The enthesis is where failures often occur in sports medicine repairs.  Tendon reattachment to the bone is a crucial clinical need, especially in larger tears, since failure rates increase linearly with tear size.

Follow Us On LinkedIn

November 14-15 • FedEx Institute of Technology in Memphis, Tennessee

Brad Patt, CEO and Andy Carter, CTO will be presenting.

Memphis makes its mark as a worldwide leader in the musculoskeletal industry by hosting the Musculoskeletal New Ventures Conference – MNVC 2023. We’re excited to be able to meet in person this year! Join us as surgeons, venture capitalists, industry leaders, and researchers gather for this one-of-a-kind opportunity to share information in the fast growing, dynamic and revolutionary field of musculoskeletal research. 

Tetrous

© Tetrous, Inc. All rights reserved.

Bradley E. Patt, PhD

Dr. Patt is cofounder chairman of Tetrous.

Brad has over 40 years experience as an entrepreneur and executive manager. He has led several enterprises from start-up phase through rapid growth and merger and acquisitions.

Brad founded several high tech ventures since 1997. He is currently co-founder chairman and CEO of TheraCell and DermOQ. Previously he was co-founder, CEO and Chairman of Gamma Medica, Inc. Brad built Gamma to market leadership position in pre­clinical CT, PET, SPECT imaging and is inventor and developer of Molecular Breast Imaging for detecting otherwise occult breast cancer in dense­breasted women.

Brad is currently co­founder and Chairman of DermOQ, Inc., an oxygen skin care company; EVO Worldwide, Inc. and spin off Smart Breast Corp., medical diagnostic imaging systems companies; and Hyvida Brands, a functional beverage startup. He is a director of High Beauty a cannabis cosmetic company. Brad also founded and is a Director of Thrive Outside the Box, a nonprofit organization that identifies and develops areas of talent in individuals on the autistic spectrum.

Brad is an internationally recognized authority in the field of medical imaging with over one hundred scientific papers and presentations, several book chapters, and over 20 patents. He has been an invited speaker at several international conferences. He has held elected positions on the IEEE Nuclear Medicine Instrumentation Steering Committee (NMISC) and the IEEE Radiation Instrumentation Steering Committee (RISC), and was appointed to the Program Committee of the SPIE Medical applications of Penetrating Radiation, acting as Chairman of the Penetrating Radiation Work Group for 2003 and 2004. Dr. Patt is a consultant to the National Institutes of Health and the recipient of over $15 million dollars of grant awards as Principal Investigator from the National Institutes of Health, The United States Department of Energy and NASA.

Bradley E. Patt, PhD

Dr. Patt is cofounder chairman of Tetrous. Brad has over 40 years experience as an entrepreneur and executive manager. He has led several enterprises from start-up phase through rapid growth and merger and acquisitions. Brad founded several high tech ventures since 1997. He is currently co-founder chairman and CEO of TheraCell and DermOQ. Previously he was co-founder, CEO and Chairman of Gamma Medica, Inc. Brad built Gamma to market leadership position in pre­clinical CT, PET, SPECT imaging and is inventor and developer of Molecular Breast Imaging for detecting otherwise occult breast cancer in dense­breasted women. Brad is currently co­founder and Chairman of DermOQ, Inc., an oxygen skin care company; EVO Worldwide, Inc. and spin off Smart Breast Corp., medical diagnostic imaging systems companies; and Hyvida Brands, a functional beverage startup. He is a director of High Beauty a cannabis cosmetic company. Brad also founded and is a Director of Thrive Outside the Box, a nonprofit organization that identifies and develops areas of talent in individuals on the autistic spectrum. Brad is an internationally recognized authority in the field of medical imaging with over one hundred scientific papers and presentations, several book chapters, and over 20 patents. He has been an invited speaker at several international conferences. He has held elected positions on the IEEE Nuclear Medicine Instrumentation Steering Committee (NMISC) and the IEEE Radiation Instrumentation Steering Committee (RISC), and was appointed to the Program Committee of the SPIE Medical applications of Penetrating Radiation, acting as Chairman of the Penetrating Radiation Work Group for 2003 and 2004. Dr. Patt is a consultant to the National Institutes of Health and the recipient of over $15 million dollars of grant awards as Principal Investigator from the National Institutes of Health, The United States Department of Energy and NASA.